Wikipedia -WSS

Wikipedia

author：entertainment 2025-09-29 22:38:24 - browse：91654

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Publishing genetic code of viruses could cause disaster

WSS

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Ultragenyx gene therapy for rare liver ailment succeeds in late

Medicare’s new pay boost for primary care is angering specialists

Today's health inequities arise from racist U.S. history, say experts

FDA's Pazdur wants cancer trials to range beyond China alone

Let's speed up science by embracing open access publishing

focus

Wikipedia

entertainment

Cancer drug shortages should be causing more outrage

Cancer diagnosis changes perspective doctor, former hospital CEO

Hollywood unions extend contract negotiations for actors

Readout Newsletter: Zepbound, Valneva's vaccine, and more

In age of alternative facts, a scholarly course on calling out crap

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Alkermes shareholders re

BMI, flaws aside, is found to be useful estimate of body fat in youth

Anesthesiologist group: stop taking Ozempic before surgery

Readout Newsletter: Zepbound, Valneva's vaccine, and more

entertainment

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

FDA's Pazdur wants cancer trials to range beyond China alone

Medical school prerequisites are outdated

What health policies could hitch a ride on a spending bill?

focus

hotspot

focus

focus